These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. [Modern possibilities of chemotherapy in patients with ductal pancreatic adenocarcinoma]. Kopchak VM; Kopchak KV; Romaniv IaV Klin Khir; 2006 Feb; (2):23-5. PubMed ID: 16826811 [TBL] [Abstract][Full Text] [Related]
9. Pressure-enabled delivery of gemcitabine in an orthotopic pancreatic cancer mouse model. Shankara Narayanan JS; Vicente DA; Ray P; Chai LF; Erdem S; Carr MJ; Capacio BA; Cox BF; Jaroch DB; Katz SC; White RR Surgery; 2020 Sep; 168(3):448-456. PubMed ID: 32620306 [TBL] [Abstract][Full Text] [Related]
10. Improved tumor control with antiangiogenic therapy after treatment with gemcitabine and nab-paclitaxel in pancreatic cancer. Zhang Z; Ji S; Hu Q; Zhuo Q; Liu W; Xu W; Liu W; Liu M; Ye Z; Fan G; Xu X; Yu X; Qin Y Clin Transl Med; 2021 Aug; 11(8):e398. PubMed ID: 34459132 [No Abstract] [Full Text] [Related]
11. [Pancreatic cancer--diagnostics and therapy]. Schramm H Zentralbl Chir; 2003 May; 128(5):367. PubMed ID: 12813632 [No Abstract] [Full Text] [Related]
12. Squalenoyl gemcitabine nanomedicine overcomes the low efficacy of gemcitabine therapy in pancreatic cancer. Réjiba S; Reddy LH; Bigand C; Parmentier C; Couvreur P; Hajri A Nanomedicine; 2011 Dec; 7(6):841-9. PubMed ID: 21419876 [TBL] [Abstract][Full Text] [Related]
13. Metronomic gemcitabine suppresses tumour growth, improves perfusion, and reduces hypoxia in human pancreatic ductal adenocarcinoma. Cham KK; Baker JH; Takhar KS; Flexman JA; Wong MQ; Owen DA; Yung A; Kozlowski P; Reinsberg SA; Chu EM; Chang CW; Buczkowski AK; Chung SW; Scudamore CH; Minchinton AI; Yapp DT; Ng SS Br J Cancer; 2010 Jun; 103(1):52-60. PubMed ID: 20531411 [TBL] [Abstract][Full Text] [Related]
14. Antitumor effect of VEGFR2-targeted microbubble destruction with gemcitabine using an endoscopic ultrasound probe: In vivo mouse pancreatic ductal adenocarcinoma model. Shimamoto N; Ito M; Chiba M; Honma S; Imazu H; Sumiyama K Hepatobiliary Pancreat Dis Int; 2020 Oct; 19(5):478-485. PubMed ID: 32265136 [TBL] [Abstract][Full Text] [Related]
15. Will gemcitabine monotherapy be dethroned as the adjuvant chemotherapy in pancreatic adenocarcinoma? Kourie HR; Gharios J; Kattan J Future Oncol; 2017 Feb; 13(3):197-199. PubMed ID: 27624286 [No Abstract] [Full Text] [Related]
16. Gemcitabine loaded microbubbles for targeted chemo-sonodynamic therapy of pancreatic cancer. Nesbitt H; Sheng Y; Kamila S; Logan K; Thomas K; Callan B; Taylor MA; Love M; O'Rourke D; Kelly P; Beguin E; Stride E; McHale AP; Callan JF J Control Release; 2018 Jun; 279():8-16. PubMed ID: 29653222 [TBL] [Abstract][Full Text] [Related]
17. ASO Author Reflections: Regulation of Chemoresistance in Pancreatic Ductal Adenocarcinoma by Scavenger Receptor CD36. Kubo M; Eguchi H Ann Surg Oncol; 2020 Feb; 27(2):620-621. PubMed ID: 31659646 [No Abstract] [Full Text] [Related]
18. CIP2A down regulation enhances the sensitivity of pancreatic cancer cells to gemcitabine. Xu P; Yao J; He J; Zhao L; Wang X; Li Z; Qian J Oncotarget; 2016 Mar; 7(12):14831-40. PubMed ID: 26894380 [TBL] [Abstract][Full Text] [Related]
19. Randomized, multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma: including a prospective evaluation of the role of hENT1 in gemcitabine or CO-101 sensitivity. Poplin E; Wasan H; Rolfe L; Raponi M; Ikdahl T; Bondarenko I; Davidenko I; Bondar V; Garin A; Boeck S; Ormanns S; Heinemann V; Bassi C; Evans TR; Andersson R; Hahn H; Picozzi V; Dicker A; Mann E; Voong C; Kaur P; Isaacson J; Allen A J Clin Oncol; 2013 Dec; 31(35):4453-61. PubMed ID: 24220555 [TBL] [Abstract][Full Text] [Related]
20. Gemcitabine-induced pulmonary toxicity in a patient with pancreatic cancer. Hiraya D; Kagohashi K; Sakamoto N; Kondo T; Satoh H JOP; 2010 Mar; 11(2):186-8. PubMed ID: 20208333 [No Abstract] [Full Text] [Related] [Next] [New Search]